Clinical Trial Update: Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure [NA]

View source ↗

Summary

PAUSE-2 is a clinical trial evaluating perioperative management of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) in patients unde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)
• Dabigatran (Dabigatran etexilate)
• Edoxaban (edoxaban)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: McMaster University | Conditions: Atrial Fibrillation (AF), VTE | NA | Status: RECRUITING